Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA.
Cell Rep. 2020 Oct 20;33(3):108276. doi: 10.1016/j.celrep.2020.108276.
Many gene products exhibit great structural heterogeneity because of an array of modifications. These modifications are not directly encoded in the genomic template but often affect the functionality of proteins. Protein glycosylation plays a vital role in proper protein functions. However, the analysis of glycoproteins has been challenging compared with other protein modifications, such as phosphorylation. Here, we perform an integrated proteomic and glycoproteomic analysis of 83 prospectively collected high-grade serous ovarian carcinoma (HGSC) and 23 non-tumor tissues. Integration of the expression data from global proteomics and glycoproteomics reveals tumor-specific glycosylation, uncovers different glycosylation associated with three tumor clusters, and identifies glycosylation enzymes that were correlated with the altered glycosylation. In addition to providing a valuable resource, these results provide insights into the potential roles of glycosylation in the pathogenesis of HGSC, with the possibility of distinguishing pathological outcomes of ovarian tumors from non-tumors, as well as classifying tumor clusters.
许多基因产物由于存在一系列修饰而表现出很大的结构异质性。这些修饰不是直接编码在基因组模板中,但经常影响蛋白质的功能。蛋白质糖基化在蛋白质的正常功能中起着至关重要的作用。然而,与其他蛋白质修饰(如磷酸化)相比,糖蛋白的分析一直具有挑战性。在这里,我们对 83 例前瞻性收集的高级别浆液性卵巢癌(HGSC)和 23 例非肿瘤组织进行了综合蛋白质组学和糖蛋白质组学分析。将来自全球蛋白质组学和糖蛋白质组学的表达数据进行整合,揭示了肿瘤特异性糖基化,揭示了与三个肿瘤簇相关的不同糖基化,并鉴定了与改变的糖基化相关的糖基化酶。除了提供有价值的资源外,这些结果还深入了解了糖基化在 HGSC 发病机制中的潜在作用,有可能区分卵巢肿瘤和非肿瘤的病理结果,以及对肿瘤簇进行分类。